Originally introduced to control blood sugar levels in type 2 diabetics, metformin in more recent years grabbed ALS researchers’ attention due to its ability to combat inflammation. Metformin is also being developed as a treatment for Huntington’s disease and multiple sclerosis.
Based on the results of preclinical studies, we think that metformin is unlikely to be of therapeutic benefit to people with ALS.
Metformin is unlikely to be useful as therapy for ALS because of its inability to extend the survival of a mouse model of ALS.
Topics in the Pipeline